ABIVAX Société Anonyme
ENXTPAABIVAX's ABVX stock exploded 39% on June 30, its biggest single-session move in months, yet the lending market tells a story of shorts who aren't backing down. The catalyst appears to be continued momentum around the phase 2b trial for ABV-1454, ABIVAX's lead program targeting inflammatory bowel disease. The stock closed at €115.50, up 35% on the week. That kind of move in a…
Snapshot as of 19 Jul 2026
ABIVAX's ABVX stock exploded 39% on June 30, its biggest single-session move in months, yet the lending market tells a story of shorts who aren't backing down. The catalyst appears to be continued momentum around the…
ABVX entered June with what should have been its finest hour. The Phase 3 ABTECT maintenance trial for obefazimod in ulcerative colitis met its primary endpoint. Instead, shares closed at €63.10 on June 2 — down 43.6%…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for ABVX — free to start on ORTEX.
Sign up for free →Open ABVX on ORTEX